Clinical Trial Update: Alendronate Versus Denosumab in Kidney Transplant Patients [Phase 2, Phase 3]

View source ↗

Summary

A randomized trial comparing alendronate to denosumab in kidney transplant recipients with osteoporosis or osteopenia has completed Phase 2/Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteopenia
• Osteoporosis
• Renal Transplant Recipient

Drugs mentioned

• Denosumab (denosumab)
• alendronate (alendronate)

Snippet

Sponsor: Ain Shams University | Conditions: Osteoporosis, Osteopenia, Renal Transplant Recipient | Phase 2, Phase 3 | Status: COMPLETED